Witnesses tell committee lead screening in pregnancy could reduce maternal complications; A4848 released

Supporters of Assembly Bill A4848 told the Assembly Communities Development and Women—s Affairs Committee that lead exposure during pregnancy is an under-recognized contributor to maternal morbidity and mortality and that routine screening could allow earlier intervention.

Elise Pivnick (introduced in the record as representing Isles, a community development and environmental organization) testified at length about lead—s health effects and racial disparities in maternal outcomes. Pivnick said lead is associated with preeclampsia and other hypertensive complications and described how lead stored in bones can be remobilized during pregnancy, increasing blood lead levels. "Lead is considered, quote, the most direct direct factor we know associated with preeclampsia," the witness said, urging the committee to vote in favor of a 4848 to standardize prenatal lead testing in New Jersey.

Support for the bill was also noted from the New Jersey State Society of Physician Assistants and Advocates for Children of New Jersey (no testimony). The witness described low cost and feasibility of blood lead testing during prenatal care and suggested clinical interventions such as calcium supplementation and lead‑safe home repair referrals for those with elevated levels.

The committee moved and released A4848 by recorded affirmative responses. Sponsors were asked to receive the witness—s written testimony and to continue discussions with stakeholders on amendment language and implementation details.